^
    1d
    CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. (PubMed, Cell Death Dis)
    By drug screening, Ibrutinib is identified as an effective inhibitor of HGSOC cells and patient-derived organoids with CBX2 condensates. Overall, CBX2 phase separation enhances DSB repair-mediated drug resistance in HGSOC cells, and Ibrutinib may offer a viable therapeutic option for CBX2-positive HGSOC patients.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • CBX2 (Chromobox 2)
    |
    Imbruvica (ibrutinib)
    1d
    IgG-κ lymphoplasmacytic lymphoma complicated by bilateral femoral neck fractures secondary to bone involvement (PubMed, Rinsho Ketsueki)
    Ibrutinib plus rituximab therapy was administered, resulting in a partial response sustained to date. Bone involvement and amyloidosis are rare but critical extranodal manifestations of LPL, necessitating careful screening and follow-up even in asymptomatic patients. When these manifestations are suspected, prompt pathological and genetic evaluation is warranted, especially in non-IgM LPL cases.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab)
    1d
    A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=3, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Completed | N=356 --> 3 | Trial completion date: Dec 2027 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib)
    2d
    Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) (clinicaltrials.gov)
    P2, N=119, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial primary completion date: Mar 2027 --> Jan 2026
    Trial primary completion date
    |
    temozolomide • Velexbru (tirabrutinib)
    2d
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq)
    3d
    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=68, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Jun 2027 --> Dec 2027
    Enrollment closed • Trial completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • temozolomide • cytarabine • etoposide IV • pegylated liposomal doxorubicin • dexamethasone
    4d
    A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. (clinicaltrials.gov)
    P3, N=2500, Recruiting, Sanofi | Active, not recruiting --> Recruiting
    Enrollment open
    4d
    FIL_COLUMN: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cytarabine • bendamustine • Zynlonta (loncastuximab tesirine-lpyl)
    6d
    A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    7d
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, BeOne Medicines | Active, not recruiting --> Completed
    Trial completion
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    8d
    MAZ-01: Zanubritnib and anti-MAG neuropathy (2025-523091-23-00)
    P1/2, N=50, Recruiting, Azienda Ospedaliera di Padova | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib)
    8d
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL (clinicaltrials.gov)
    P2, N=145, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Gazyva (obinutuzumab) • Inokai (orelabrutinib)